Cubist Pharmaceutical 1Q Profit Rises 45% On Strong Sales .

Cubist Pharmaceuticals Inc.'s (CBST) first-quarter earnings rose 45% as strong sales of the biopharmaceutical company's infection-fighting drug Cubicin boosted revenue. 

Shares were up 2% at $41.50 in recent after-hours trading as the results beat expectations. Through the close, the stock has risen nearly 29% in the past ...

No comments:

Post a Comment

Superhit News

News Archive